Type 2 immunity: a two-edged sword in schistosomiasis immunopathology

Area of Science:

• Immunology
• Tropical Medicine
• Pathology

Background:

• Schistosomiasis is a globally significant neglected tropical disease, second only to malaria in its debilitating impact.
• Current therapeutic options for schistosomiasis do not address disease-driven immunopathology.
• The immune response to schistosomiasis is heterogeneous, with type 2 immunity being dominant after egg deposition (oviposition).

Purpose of the Study:

• To review recent advancements in understanding schistosomiasis immunopathology.
• To elucidate the roles of various cells and signaling pathways in regulating type 2 immunity during schistosomiasis.
• To highlight the importance of comprehending these immune responses for future therapeutic development.

Main Methods:

• Review of current literature on schistosomiasis immunology.
• Analysis of cellular and molecular mechanisms driving type 2 immune responses.
• Discussion of signaling pathways involved in immune regulation.

Main Results:

• Type 2 immunity is crucial for granuloma formation and host survival in acute schistosomiasis.
• Chronic activation of type 2 immunity contributes to tissue scarring, fibrosis, and organ damage.
• Diverse immune and non-immune cells and signaling pathways are implicated in the modulation of type 2 immunity.

Conclusions:

• A comprehensive understanding of type 2 immunity in schistosomiasis is essential.
• Targeting and fine-tuning type 2 immunity holds promise for novel therapeutic strategies.
• Developing therapies to modulate schistosomiasis immunopathology can improve patient outcomes.